News | August 26, 2025
Merck presents new data on cardiovascular disease at ESC Congress 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Subscribe To Our Newsletter & Stay Updated
